Bavarian Nordic (OTCMKTS:BVNRY) Shares Gap Up – Still a Buy?

Bavarian Nordic (OTCMKTS:BVNRY)’s share price gapped up before the market opened on Monday . The stock had previously closed at $9.76, but opened at $10.00. Bavarian Nordic shares last traded at $10.00, with a volume of 264 shares.

Bavarian Nordic Stock Performance

The firm has a market capitalization of $2.34 billion, a PE ratio of 6.36 and a beta of 1.37. The stock has a fifty day moving average price of $10.26 and a 200-day moving average price of $10.90.

Bavarian Nordic (OTCMKTS:BVNRY) last issued its quarterly earnings data on Friday, November 14th. The company reported $0.72 earnings per share for the quarter. Bavarian Nordic had a return on equity of 20.47% and a net margin of 35.96%.The company had revenue of $281.11 million for the quarter. Research analysts expect that Bavarian Nordic will post 0.67 earnings per share for the current fiscal year.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.